Remote Director, Oncology Clinical Trial BD & Delivery

Massive Bio, Inc.; North Carolina; Remote; USD 180,000 - 240,000; Full time

Job summary

Massive Bio, Inc. seeks a Director of Business Development & Client Delivery to lead the end-to-end sponsor engagement process, from initial outreach through readout and contract execution.

You will own the sponsor relationship, manage proposals, and ensure compliant close-out documentation, working closely with Product and QA teams. You will collaborate with oncology sponsors across the US and internationally, guiding EDC and data‑use terms, while driving pilots into multi‑study agreements and

Qualifications

• 7+ years in US clinical research with hands-on data side experience (CRF entry, SDV).
• Sponsor-facing business development and account management experience.
• Proven ability to convert pilots to contracts and manage master agreements.

Responsibilities

• Lead business development and client delivery (80%) with oncology sponsors.
• Own sponsor relationships from kickoff to readout and drive multi-study agreements.
• Draft Statements of Work under master agreements and manage paper trails for new partners.
• Price services per rate card and handle discount approvals within policy.
• Support close-out deliverables and ensure regulatory alignment in documentation.

Skills

Clinical research

Business development

Account management

FDA/EMA knowledge

CRF/EDC experience

Pilot-to-contract selling

SOW drafting

Tools

Medidata Rave

Oracle Clinical One

InForm

Veeva Vault EDC

Job description

Massive Bio, Inc. seeks a Director of Business Development & Client Delivery to lead the end-to-end sponsor engagement process, from initial outreach through readout and contract execution.

You will own the sponsor relationship, manage proposals, and ensure compliant close-out documentation, working closely with Product and QA teams. You will collaborate with oncology sponsors across the US and internationally, guiding EDC and data‑use terms, while driving pilots into multi‑study agreements and